Development of novel dendritic -cell vaccine with biodegradable nanoparticles for tuberculosis

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09214
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: SUDA TAKAFUMI 浜松医科大学, 医学部, 教授 (30291397)
• Co-Investigator(Kenkyū-buntansha): 榎本 紀之 浜松医科大学, 医学部附属病院, 講師 (50436961) ; 中村 祐太郎 浜松医科大学, 医学部附属病院, 講師 (60436962) ; 永田 年 浜松医科大学, 医学部, 教授 (90275024)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: ワクチン / 樹状細胞 / 結核 / 細胞内寄生菌

Outline of Final Research Achievements

We attempted to develop a novel cell-based vaccine using dendritic cells (DC) and biodegradable polylactic glycolic acid (PLGA)-nanoparticles (PLGA) for intracellular infections, such as tuberculosis. Bone marrow-derived DC pulsed with PLGA, which was coated with ovalbumin protein (OVA) (DC-PLGA/OVA), potently induced a peptide-specific T cell response through efficient cross-presentation in vitro, assessed by peptide-specific T cell proliferation and IFN-gamma production. However, in vivo, immunization with DC-PLGA/OVA failed to elicit a strong peptide-specific T cell response, based on the results of peptide-specific T cell proliferation and the number of peptide-specific T cell determined with tetramer.

Free Research Field

呼吸器内科